Premium
Molecular characterization and multidisciplinary management of Gerbich hemolytic disease of the newborn
Author(s) -
Levitt Rebecca N.,
Gourri Elise,
Gassner Christoph,
BanezSese Grace,
Salam Abdus,
Denomme Gregory A.,
Yang Elizabeth
Publication year - 2018
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.27014
Subject(s) - medicine , phenotype , immunology , obligate , glycophorin , disease , antibody , fetus , red blood cell , antigen , heterozygote advantage , gene , pregnancy , genetics , biology , allele , ecology
Gerbich (Ge) antigens are high frequency red cell antigens expressed on glycophorin C (GYPC) and glycophorin D. Hemolytic disease of the fetus and newborn (HDFN) due to Gerbich antibody is rare and presents a clinical challenge, as Gerbich negative blood is scarce. We report a case of HDFN due to maternal Ge3 negative phenotype and anti‐Ge3 alloimmunization, successfully managed by transfusion of maternal blood. Molecular testing revealed that the mother has homozygous deletion of exon 3 of GYPC , the father is homozygous wildtype for GYPC , and the infant is obligate heterozygote expressing Ge3.